Form 4: Teva Pharmaceutical Industries Executive Mark Sabag Reports Share Transactions
SEC Form 4
Mark Sabag, Executive Vice President at Teva Pharmaceutical Industries, reports the vesting and disposal of restricted share units resulting in changes to his beneficial ownership of ordinary shares.
Summary
- Mark Sabag, an Executive Vice President at Teva Pharmaceutical Industries, filed a Form 4 detailing changes in his beneficial ownership of Teva shares.
- On March 4, 2025, restricted share units vested and were subsequently disposed of.
- These transactions involved the vesting of 33,512 units granted on March 4, 2022, 18,601 units granted on March 4, 2024, and 183,169 units granted on January 28, 2025.
- The vesting of these restricted share units resulted in the acquisition of ordinary shares, which were then disposed of.
- Following these transactions, Sabag's direct ownership includes 0 ordinary shares and 55,803 restricted share units.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, so the sentiment is neutral.
Industry Context
Form 4 filings are a routine part of compliance for corporate insiders and provide transparency into their transactions in company stock.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership by a company executive.
Key Dates
| Date | Description |
|---|---|
| 03/04/2022 | Grant date of 33,512 restricted share units. |
| 03/04/2023 | Vesting date of 33,512 restricted share units. |
| 03/04/2024 | Grant date of 18,601 restricted share units and vesting date of 33,512 restricted share units. |
| 01/28/2025 | Grant date of 183,169 restricted share units. |
| 03/04/2025 | Date of transactions: vesting and disposal of restricted share units. |
| 03/04/2026 | Vesting date of 33,512 and 18,601 restricted share units. |
| 03/04/2027 | Vesting date of 18,601 restricted share units. |
| 03/04/2028 | Vesting date of 18,601 restricted share units. |
| 03/06/2025 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.